-
1.发明授权Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma 失效用于抑制与前列腺腺癌相关的肿瘤的药物制剂
公开(公告)号：US5428011A
公开(公告)日：1995-06-27
申请号：US899535
申请日：1992-06-16
申请人： Anil R. Sheth , Seema Garde , Chandra J. Panchal
发明人： Anil R. Sheth , Seema Garde , Chandra J. Panchal
IPC分类号： A61K9/127 , A61K31/40 , A61K31/405 , A61K31/505 , A61K31/65 , A61K31/70 , A61K33/24 , A61K38/22 , A61P35/00 , A61K38/00 , C07K5/00 , C07K7/00 , C07K14/00
CPC分类号： A61K38/22
摘要： The present invention provides pharmaceutical preparations for inhibiting in-vitro and in-vivo cancerous prostate, gastrointestinal and breast tumors. In one embodiment the pharmaceutical preparation includes human seminal prostatic inhibin which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from prostate cancer. In another embodiment the pharmaceutical preparation includes a mixture of human seminal prostatic inhibin and a anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example gastrointestinal cancer. The anticancer drug of the latter mixture may be one selected from the group of drugs including mitomycin, idalubicin, cisplatin, 5-fluorouracil, methotrexate, adriamycin and daunomycin.
摘要翻译： 本发明提供用于抑制体外和体内癌前列腺，胃肠道和乳腺肿瘤的药物制剂。 在一个实施方案中，药物制剂包括人类前列腺抑制素，其可以以适当的剂型，剂量和剂量方案给予患有前列腺癌的患者。 在另一个实施方案中，药物制剂包括人类前列腺抑制素和抗癌药物的混合物，其可以以适当的剂型，剂量和剂量方案给予患有例如胃肠癌的患者。 后者混合物的抗癌药可以是选自丝裂霉素，依达比星，顺铂，5-氟尿嘧啶，甲氨蝶呤，阿霉素和道诺霉素的药物组。
-
2.发明申请Method and Composition For Treating Angiogenesis and For Preventing Cancer Progression and Metastasis Comprising a Prostate Secretory Protein (Psp94) Family Member 审中-公开用于治疗血管生成和预防包括前列腺分泌蛋白（Psp94）家族成员的癌症进展和转移的方法和组合物公开(公告)号：US20080200393A1
公开(公告)日：2008-08-21
申请号：US11628392
申请日：2005-03-21
申请人： Chandra J. Panchal , Jinzi Jason Wu , Richard Beliveau , Marcia Ruiz , Seema Garde , Borhane Annabi , Sylvie Lamy , Mounia Bouzeghrane , Luc Daigneault , Robert Hawkins
发明人： Chandra J. Panchal , Jinzi Jason Wu , Richard Beliveau , Marcia Ruiz , Seema Garde , Borhane Annabi , Sylvie Lamy , Mounia Bouzeghrane , Luc Daigneault , Robert Hawkins
摘要： Angiogenesis, the formation of new blood vessels, is an integral part of normal physiological and developmental processes as well as several pathologies, ranging from tumor growth and metastasis to inflammation and ocular disease. Methods and compositions are provided for controlling normal angiogenesis and for treating angiogenesis associated or mediated diseases as well as for preventing cancer progression and metastasis through the use of a prostrate secretory protein (PSP) family member.
摘要翻译： 血管生成新血管的形成是正常的生理和发育过程以及从肿瘤生长和转移到炎症和眼部疾病的几种病理学的组成部分。 提供了用于控制正常血管发生和治疗血管生成相关或介导的疾病以及通过使用前列腺分泌蛋白（PSP）家族成员来预防癌症进展和转移的方法和组合物。
-
公开(公告)号：US20050148514A1
公开(公告)日：2005-07-07
申请号：US11004273
申请日：2004-12-02
申请人： Chandra Panchal , Jinzi Wu , Richard Beliveau , Marcia Ruiz , Seema Garde , Borhane Annabi , Sylvie Lamy , Mounia Bouzeghrane , Luc Daigneault , Robert Hawkins
发明人： Chandra Panchal , Jinzi Wu , Richard Beliveau , Marcia Ruiz , Seema Garde , Borhane Annabi , Sylvie Lamy , Mounia Bouzeghrane , Luc Daigneault , Robert Hawkins
CPC分类号： A61K38/10 , A61K38/1709 , C07K14/47 , C12N9/6491
摘要： Angiogenesis, the formation of new blood vessels, is an integral part of normal physiological and developmental processes as well as several pathologies, ranging from tumor growth and metastasis to inflammation and ocular disease. Methods and compositions are provided for controlling normal angiogenesis and for treating angiogenesis associated or mediated diseases.
摘要翻译： 血管生成新血管的形成是正常的生理和发育过程以及从肿瘤生长和转移到炎症和眼部疾病的几种病理学的组成部分。 提供了用于控制正常血管发生和治疗血管生成相关或介导的疾病的方法和组合物。
-
公开(公告)号：US20100239653A1
公开(公告)日：2010-09-23
申请号：US12692225
申请日：2010-01-22
摘要： The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer. The anticancer drug of the latter mixture may be one selected from the group of drugs including mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
摘要翻译： 本发明提供用于抑制前列腺腺癌，胃癌，乳腺癌，子宫内膜，卵巢或其它上皮分泌癌或良性前列腺增生（BPH）的生长的药物组合物和方法。 在一个实施方案中，药物组合物包括人rHuPSP94，其抗原部分和其功能上等同的多肽。 在另一个实施方案中，药物组合物包括人rHuPSP94，其抗原部分和其功能等同多肽的混合物，以及抗癌药物，其可以以适当的剂型，剂量和剂量方案施用于患有例如 前列腺腺癌，胃癌，乳腺癌，子宫内膜癌，卵巢癌或其他上皮分泌性癌症，良性前列腺增生或（BPH）胃肠癌。 后者混合物的抗癌药可以是选自丝裂霉素，伊达比星，顺铂，5-氟尿嘧啶，甲氨蝶呤，阿霉素，道宁霉素，紫杉醇，紫杉醇衍生物及其混合物的药物组。
-
公开(公告)号：US07655631B2
公开(公告)日：2010-02-02
申请号：US11240937
申请日：2005-09-30
摘要： The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH) In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer. The anticancer drug of the latter mixture may be one selected from the group of drugs including mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
摘要翻译： 本发明提供用于抑制前列腺腺癌，胃癌，乳腺癌，子宫内膜，卵巢癌或其他上皮分泌性癌症或良性前列腺增生症（BPH）的生长的药物组合物和方法。在一个实施方案中，药物组合物包括人rHuPSP94，其抗原部分 ，及其功能上相当的多肽。 在另一个实施方案中，药物组合物包括人rHuPSP94，其抗原部分和其功能等同多肽的混合物，以及抗癌药物，其可以以适当的剂型，剂量和剂量方案施用于患有例如 前列腺腺癌，胃癌，乳腺癌，子宫内膜癌，卵巢癌或其他上皮分泌性癌症，良性前列腺增生或（BPH）胃肠癌。 后者混合物的抗癌药可以是选自丝裂霉素，伊达比星，顺铂，5-氟尿嘧啶，甲氨蝶呤，阿霉素，道宁霉素，紫杉醇，紫杉醇衍生物及其混合物的药物组。
-
公开(公告)号：US20080182777A1
公开(公告)日：2008-07-31
申请号：US11807589
申请日：2007-05-29
申请人： Chandra J. Panchal , Jinzi Jason Wu , Richard Beliveau , Marcia Ruiz , Seema Garde , Borhane Annabi , Sylvie Lamy , Mounia Bouzeghrane , Luc Daigneault , Robert Hawkins
发明人： Chandra J. Panchal , Jinzi Jason Wu , Richard Beliveau , Marcia Ruiz , Seema Garde , Borhane Annabi , Sylvie Lamy , Mounia Bouzeghrane , Luc Daigneault , Robert Hawkins
IPC分类号： A61K38/00
CPC分类号： A61K38/1709 , A61K38/10 , A61K38/17 , A61K38/46 , A61K38/52 , A61K48/00 , C07H21/04 , C07K14/47 , C12N9/64 , C12N9/6491 , C12Q1/68
摘要： Matrix metalloproteinases (MMPs) play an important role in morphogenesis, angiogenesis, wound healing, and in certain disorders such as rheumatoid arthritis, tumor invasion and metastasis. MMPs are thought to be regulated by a variety of cytokines, growth factors, hormones and phorbol esters. This regulation occurs on three levels; alteration of gene expression, activation of the latent zymogen and inhibition by the tissue inhibitors of metalloproteinases (TIMP). We report here a new agent that regulates the level of MMPs.
摘要翻译： 基质金属蛋白酶（MMP）在形态发生，血管生成，伤口愈合以及某些疾病如类风湿性关节炎，肿瘤浸润和转移中起重要作用。 认为MMP被多种细胞因子，生长因子，激素和佛波酯所调节。 这种规定发生在三个层次上 基因表达的改变，潜在酶原的活化和金属蛋白酶（TIMP）的组织抑制剂的抑制。 我们在这里报告一种调节MMPs水平的新药物。
-
公开(公告)号：US08551951B2
公开(公告)日：2013-10-08
申请号：US12692225
申请日：2010-01-22
摘要： The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer. The anticancer drug of the latter mixture may be one selected from the group of drugs including mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
-
公开(公告)号：US20060105949A1
公开(公告)日：2006-05-18
申请号：US11240937
申请日：2005-09-30
摘要： The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH) In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer. The anticancer drug of the latter mixture may be one selected from the group of drugs including mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
摘要翻译： 本发明提供用于抑制前列腺腺癌，胃癌，乳腺癌，子宫内膜，卵巢癌或其他上皮分泌性癌症或良性前列腺增生症（BPH）的生长的药物组合物和方法。在一个实施方案中，药物组合物包括人rHuPSP94，其抗原部分 ，及其功能上相当的多肽。 在另一个实施方案中，药物组合物包括人rHuPSP94，其抗原部分和其功能等同多肽的混合物，以及抗癌药物，其可以以适当的剂型，剂量和剂量方案施用于患有例如 前列腺腺癌，胃癌，乳腺癌，子宫内膜癌，卵巢癌或其他上皮分泌性癌症，良性前列腺增生或（BPH）胃肠癌。 后者混合物的抗癌药可以是选自丝裂霉素，伊达比星，顺铂，5-氟尿嘧啶，甲氨蝶呤，阿霉素，道宁霉素，紫杉醇，紫杉醇衍生物及其混合物的药物组。
-
公开(公告)号：US07053058B2
公开(公告)日：2006-05-30
申请号：US09977406
申请日：2001-10-15
IPC分类号： A61K38/18 , A61K38/16 , C07K14/475
摘要： The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer. The anticancer drug of the latter mixture may be one selected from the group of drugs including mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
-
公开(公告)号：US20050147601A1
公开(公告)日：2005-07-07
申请号：US11004270
申请日：2004-12-02
申请人： Chandra Panchal , Jinzi Wu , Richard Beliveau , Marcia Ruiz , Seema Garde , Borhane Annabi , Sylvie Lamy , Mounia Bouzeghrane , Luc Daigneault , Robert Hawkins
发明人： Chandra Panchal , Jinzi Wu , Richard Beliveau , Marcia Ruiz , Seema Garde , Borhane Annabi , Sylvie Lamy , Mounia Bouzeghrane , Luc Daigneault , Robert Hawkins
IPC分类号： A61K38/10 , A61K38/17 , A61K38/46 , A61K38/52 , A61K48/00 , A61P35/00 , C07H21/04 , C07K14/47 , C12N9/64 , C12Q1/68
CPC分类号： A61K38/1709 , A61K38/10 , A61K38/17 , A61K38/46 , A61K38/52 , A61K48/00 , C07H21/04 , C07K14/47 , C12N9/64 , C12N9/6491 , C12Q1/68
摘要： Matrix metalloproteinases (MMPs) play an important role in morphogenesis, angiogenesis, wound healing, and in certain disorders such as rheumatoid arthritis, tumor invasion and metastasis. MMPs are thought to be regulated by a variety of cytokines, growth factors, hormones and phorbol esters. This regulation occurs on three levels; alteration of gene expression, activation of the latent zymogen and inhibition by the tissue inhibitors of metalloproteinases (TIMP). We report here a new agent that regulates the level of MMPs.
摘要翻译： 基质金属蛋白酶（MMP）在形态发生，血管生成，伤口愈合以及某些疾病如类风湿性关节炎，肿瘤浸润和转移中起重要作用。 认为MMP被多种细胞因子，生长因子，激素和佛波酯所调节。 这种规定发生在三个层次上 基因表达的改变，潜在酶原的活化和金属蛋白酶（TIMP）的组织抑制剂的抑制。 我们在这里报告一种调节MMPs水平的新药物。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.015 秒)
